Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Optimizing mesenchymal stromal cells priming strategies for tailored effects on the secretome.

González-Rodríguez Y., Casado-Santos A., González-Cubero E., González-Fernández ML., Sellés-Egea A., Villar-Suárez V.

Laboratory Study on Chronic Inflammation, Immune Modulation, published in Biomed Pharmacother (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Biomed Pharmacother (2025)
Country
France
Reported sample size
—
Source database
PubMed
PMID
40446445
DOI
10.1016/j.biopha.2025.118218

Abstract (original English)

Mesenchymal stromal cells (MSCs) have emerged as a promising tool in regenerative medicine, with recent focus shifting towards their secretome as a cell-free therapeutic approach. This study investigates the impact of various priming strategies on the immunomodulatory, anti-inflammatory, and regenerative potential of adipose-derived MSCs (ASCs) secretomes. We evaluated the effects of hypoxia, pro-inflammatory cytokines, and spheroid culture conditions on ASC secretome composition and functionality. Gene expression analysis, nanoparticle tracking, protein quantification, and functional assays were performed to characterize the secretomes. RNA sequencing revealed significant differences in gene expression profiles across priming conditions, particularly in pathways related to osteogenesis, angiogenesis, inflammation, and neurotrophic factors. Notably, spheroid culture combined with hypoxia and inflammation resulted in a substantial increase in extracellular vesicle production and altered protein content. Functional assays demonstrated enhanced neutrophil inhibition by secretomes from hypoxia-primed ASCs. Our findings indicate that tailored priming strategies can significantly modulate the therapeutic properties of ASC secretomes, potentially enhancing their efficacy in various clinical applications. This study provides valuable insights for optimizing cell-free therapies in regen

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsSecretomeHumansCells, CulturedAdipose TissueCytokinesRegenerative MedicineCell HypoxiaSpheroids, CellularExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research